About Us

Gelomics is revolutionizing drug development by enabling the growth of human tissue models in vitro. This provides an ethical, cost-effective, and predictive alternative to animal testing.

Leadership

The Gelomics leadership team is composed of experienced professionals. They are dedicated to advancing the company’s vision of transforming drug discovery through innovative 3D cell culture solutions.

C Meinert_Gelomics copy

Christoph Meinert, PhD

Co-founder and CEO
P Levett_Colour

Peter Levett, PhD

Co-founder and COO
Emma M

Emma Morris, BSc

Sales and Applications Specialist
HZ

Hayley Zhang, BBus

Marketing Manager
PM copy

Pawel Mieszczanek, PhD

Lead Engineer
FS copy

Farhad Soheil, PhD

R&D Scientist

Scientific Advisory Board

These distinguished leaders in their fields bring a wealth of knowledge and expertise to Gelomics, therefore driving our mission of revolutionizing drug development with cutting-edge 3D cell culture technology.

Professor Dame Molly Stevens, PhD, FREng FRS

Oxford University

“Gelomics are developing exciting biomaterials technology that aligns with a sustainable future in biomedical research and development. I look forward to contributing my expertise to advance their ground-breaking work.”

Professor Stevens is the John Black Professor of Bionanoscience at Oxford University, serving in the Institute for Biomedical Engineering and the Department of Physiology, Anatomy, and Genetics. Additionally, she is Deputy Director of the Kavli Institute for Nanoscience Discovery. Holding a PhD from the University of Nottingham and postdoctoral experience at MIT, she led research at Imperial College London and remains part-time faculty. Additionally, she is a Biomaterials Professor at Karolinska Institutet. Recognized for her work in biosensing, regenerative medicine, and therapeutics, she has published over 400 papers and holds numerous patents, including four spin-out companies. Furthermore, Prof. Stevens has received over 40 awards, including the Novo Nordisk Award (2023), and is a Fellow of several prestigious institutions, such as the Royal Society.

Distinguished Prof. Dietmar W. Hutmacher, PhD, MBA

Queensland University of Technology (QUT)

“I’m excited to contribute to Gelomics’ pioneering efforts, to support the biomaterials science and tissue engineering and regenerative medicine community with products which allow to strive for reproducibility and enhancement of translational readiness levels of their research endevours.”

Professor Hutmacher, co-founder of Gelomics, and current Director of the Max Planck Queensland Centre for the Materials Science of Extracellular Matrices, is a globally recognised leader in tissue engineering and regenerative medicine. With decades of industrial and academic excellence, Professor Hutmacher has pioneered numerous biomedical innovations. Moreover, he has authored over 500 journal articles, edited 14 books, and holds an h-index of 133 with over 75,000 citations. As a result, his role at Gelomics will leverage his expertise in translating research into commercial and clinical applications, driving biomaterials technology forward.

Professor Travis Klein, PhD

Queensland University of Technology (QUT)

“I am thrilled to join Gelomics’ Scientific Advisory Board and support the development of innovative, non-animal methodologies that pave the way for more ethical and efficient drug development.”

Professor Klein, also a co-founder of Gelomics, is a distinguished figure in the field of biomedical engineering at the Queensland University of Technology (QUT). As leader of the Cartilage Regeneration Laboratory, he develops regenerative therapies for cartilage defects. His senior QUT roles and 10,000+ citations will be invaluable as Gelomics pioneers innovative, non-animal drug development methodologies.

Subscribe Now!